Verastem Oncology
Verastem, Inc. is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s lead hematology product candidate is duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met the primary endpoints in both a Phase 2 study in double-refractory iNHL and a Phase 3 clinical trial in patients with relapsed/refractory CLL/SLL.